INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
- 1 April 1998
- journal article
- review article
- Published by Annual Reviews in Annual Review of Immunology
- Vol. 16 (1) , 27-55
- https://doi.org/10.1146/annurev.immunol.16.1.27
Abstract
▪ Abstract The interleukin-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family that binds to IL-1 receptors but does not induce any intracellular response. Two structural variants of IL-1Ra have previously been described: a 17-kDa form that is secreted from monocytes, macrophages, neutrophils, and other cells (sIL-1Ra) and an 18-kDa form that remains in the cytoplasm of keratinocytes and other epithelial cells, monocytes, and fibroblasts (icIL-1Ra). An additional 16-kDa intracellular isoform of IL-1Ra has recently been described in neutrophils, monocytes, and hepatic cells. Both of the major isoforms of IL-1Ra are transcribed from the same gene through the use of alternative first exons. The two promoters regulating transcription of the secreted and intracellular forms have been cloned, and some of the functional cis-acting DNA regions have been characterized. The production of IL-1Ra is stimulated by many substances including adherent IgG, other cytokines, and bacterial or viral components. The tissue distribution of IL-1Ra in mice indicates that sIL-1Ra is found predominantly in peripheral blood cells, lungs, spleen, and liver, while icIL-1Ra is found in large amounts in skin. Studies in transgenic and knockout mice indicate that IL-1Ra is important in host defense against endotoxin-induced injury. IL-1Ra is produced by hepatic cells with the characteristics of an acute phase protein. Endogenous IL-1Ra is produced in numerous experimental animal models of disease as well as in human autoimmune and chronic inflammatory diseases. The use of neutralizing anti-IL-1Ra antibodies has demonstrated that endogenous IL-1Ra is an important natural antiinflammatory protein in arthritis, colitis, and granulomatous pulmonary disease. Treatment of human diseases with recombinant human IL-1Ra showed an absence of benefit in sepsis syndrome. However, patients with rheumatoid arthritis treated with IL-1Ra for six months exhibited improvements in clinical parameters and in radiographic evidence of joint damage.Keywords
This publication has 151 references indexed in Scilit:
- Interleukin-1 receptor antagonist: Discovery, structure and propertiesPublished by Elsevier ,2004
- Interleukin-1 Receptor and Receptor Antagonist Gene Expression After Focal Stroke in RatsStroke, 1997
- Circulating and Ex Vivo Production of Pyrogenic Cytokines and Interleukin-1 Receptor Antagonist in 123 Patients with Fever of Unknown OriginThe Journal of Infectious Diseases, 1997
- In Vivo Regulation of the IL-1β System (Ligand, Receptors I and II, Receptor Accessory Protein, and Receptor Antagonist) and TNF-α mRNAs in Specific Brain RegionsBiochemical and Biophysical Research Communications, 1996
- The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradationOsteoarthritis and Cartilage, 1996
- Fluorescence Resonance Energy Transfer Reveals Interleukin (IL)-1-dependent Aggregation of IL-1 Type I Receptors That Correlates with Receptor ActivationPublished by Elsevier ,1995
- Induction of Interleukin-1 Receptor Antagonist (IL-1ra) Following Surgery Is Associated with Major TraumaClinical Immunology and Immunopathology, 1995
- METHOTREXATE ACTION IN RHEUMATOID ARTHRITIS: STIMULATION OF CYTOKINE INHIBITOR AND INHIBITION OF CHEMOKINE PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLSRheumatology, 1995
- Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist proteinEuropean Journal of Immunology, 1991
- Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitroImmunology Today, 1991